Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study.

Autor:	Almeida A; Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal., Ferreira AR; Serviço de Hematologia, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal., Costa MJ; Serviço de Hematologia, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal., Silva S; Serviço de Hematologia, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal., Alnajjar K; Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal., Bogalho I; Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal., Pierdomenico F; Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal., Esteves S; Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal., Alpoim M; Serviço de Hematologia, Hospital São João, Porto, Portugal., Braz G; Serviço de Hematologia, Hospital São João, Porto, Portugal., Cortesão E; Serviço de Hematologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal., Pinto R; Serviço de Hematologia, Hospital São João, Porto, Portugal.
Jazyk:	angličtina
Zdroj:	Leukemia research reports [Leuk Res Rep] 2016 Dec 23; Vol. 7, pp. 6-10. Date of Electronic Publication: 2016 Dec 23 (Print Publication: 2017).
DOI:	10.1016/j.lrr.2016.12.002
Abstrakt:	Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu